Rationale and Design of a Randomized, Double-Blind, Event-Driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial
Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Roger M. Mills(Janssen (Belgium)), Barry Greenberg(University of California San Diego), William M. Byra(Janssen (United States)), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Min Fu(Janssen (United States)), Mihai Gheorghiade(Northwestern University), John G.F. Cleland(University of Glasgow), Dirk J. Van Veldhuisen(University Medical Center Groningen), Mandeep R. Mehra(Harvard University)
Cited by 78
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
2018 ESC/ESH Guidelines for the management of arterial hypertension
|European Heart Journal|2018|10.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k